We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




POC Diagnostic Kits Targeted for Resource-Limited Areas

By LabMedica International staff writers
Posted on 24 Mar 2011
A biotechnology company intends to develop new point of care (POC) diagnostic technologies, which are targeted for use in resource-limited settings.

The technologies will be geared toward the development of noninvasive, urine-based, rapid detection systems for the diagnosis of a panel of sexually transmitted infections, in addition to other diseases such as Tuberculosis.

The company, Norgen Biotek (Thorold, ON, Canada) received over US$800,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP; Ottawa, ON, Canada).

The company focuses primarily on advancing powerful tools for nucleic acids (NA) and protein purification and preservation, as well as developing leading-edge diagnostic tools.

With the new funding Norgen will focus on the development of POC human diagnostic kits for use in resource-limited areas, as well as for home use testing. More...
The new technologies will rely on the use of noninvasive specimens such as urine and saliva for ease of use and cost reduction. Norgen's purification technology is extremely well suited for use in resource-limited settings, as Norgen's resin is able to isolate and concentrate DNA, RNA, and proteins from samples without the use of centrifugation or other equipment.

Norgen has developed technologies and products for the purification of nucleic acids and proteins on both preparative and industrial scales, including ready-to-use chromatography resins and prepacked chromatography columns.

Related Links:

Norgen Biotek
National Research Council of Canada Industrial Research Assistance Program



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.